Swiss researchers utilize drug repurposing to address rare disease therapies

Researchers in Switzerland are successfully identifying therapeutic applications for rare diseases by repurposing existing, well-known pharmaceutical ingredients. This approach accelerates development timelines and reduces costs compared to traditional de novo drug discovery, though the long-term efficacy and regulatory approval pathways for these specific applications remain to be fully established.